Description:

In April 2018, after a rigorous preregistered clinical trial that was published in the journal Nature Digital Medicine, the U.S. Food and Drug Administration (FDA) de novo authorized IDx-DR® the first autonomous AI system.  IDx-DR diagnoses (DR) and macular edema in adults who have diabetes and identifies those who need to be referred to eye care.   Two years later in November 2020, EyeArt® was 510k cleared by the FDA to market a similar device.  Based on claims data across all insured, only 15.3% of diabetic patients are receiving annual eye exams.  To tackle this gap in care, healthcare providers are implementing point-of-care tests utilizing autonomous AI technology to complete these diabetic retinal exams outside traditional eyecare settings.  This continuing education will not only reveal how AI technology is changing the way DR and macular edema are identified, but it will also help optometrists prepare for this rapidly evolving healthcare delivery model.

Course Code:

AOA223-PB

Speaker(s):

Dana Weitzman, O.D.
dena.weitzman@gmail.com

Credits:

1

AOA Expiration Date:

3/3/2025

Related News

Lawmakers host AOA, patient and consumer advocates for VBM abuse briefing as Congress expands probes

At the request of a key U.S. House committee, AOA and patient and consumer advocates briefed lawmakers and staff on growing vision benefit manager (VBM) abuses as Capitol Hill leaders increasingly probe their costly, controlling and care-limiting schemes.

Are you ready for the Eyeglass Rule of 2024?

The Federal Trade Commission issued its updated Eyeglass Rule after an extended review. The rule, which takes effect Sept. 24, requires doctors of optometry to get patient confirmation that they had received a copy of their prescription at the completion of an eye exam.

On the radar: Emerging technologies

The AOA’s New Technology Committee shares five areas they are investigating and how they might affect your practice.